Search
EHA-SLCH Hematology Tutorial on Hematological Disorders
Date: March 18-19, 2022
Format: Hybrid
EHA and the Sri Lanka College of Haematologists (SLCH) are happy to have successfully organized the EHA-SLCH Hematology Tutorial on Hematological Disorders on March 18 and 19, 2022.
EHA25 Virtual | News Room
Welcome to the news room of EHA25 Virtual where you can find the most relevant news items.
Read moreWithout access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
In Memoriam Jean Claude Brouet
Professor Jean Claude Brouet passed away on December 12, 2022 at the age of 80.
Read moreClinical Practice Guidelines
EHA creates clinical practice Guidelines for diagnosis and treatment of hematologic diseases. This initiative started in 2019 with the establishment of the EHA Guidelines Committee and the definition of the EHA Methodology for Guidelines.
Read moreEHA Guidelines by Topic
AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Bleeding and thrombosis
EHA Guidelines on management of antithrombotic treatments…
SWG Educational Activities
Social and public activitiesSince 2020, Prof Hermann Einsele has been a Councilor to the EHA Board. Scientific activitiesFifth European CAR T-cell meetingDateFebruary 9–11, 2023. LocationRotterdam, The Netherlands.
Read moreHighlights from the SWG
The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.
Read morePublications
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- »